Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative products
based on its proprietary, transdermal DermaSys® drug delivery technology
and currently focused on sexual health and pain, today announces it has
entered into a licensing agreement with A. Menarini Korea Limited
("Menarini Korea"), a wholly owned subsidiary of Menarini Group, for the
exclusive rights to commercialise the Company's topical, gel-based
Erectile Dysfunction ("ED") treatment MED3000 in South Korea.
More info >> |